1RMJ image
Deposition Date 2003-11-28
Release Date 2004-09-14
Last Version Date 2024-11-20
Entry Detail
PDB ID:
1RMJ
Title:
C-terminal domain of insulin-like growth factor (IGF) binding protein-6: structure and interaction with IGF-II
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Conformers Calculated:
50
Conformers Submitted:
20
Selection Criteria:
structures with the lowest energy
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Insulin-like growth factor binding protein 6
Gene (Uniprot):IGFBP6
Chain IDs:A
Chain Length:107
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
C-terminal domain of insulin-like growth factor (IGF) binding protein-6: structure and interaction with IGF-II.
Mol.Endocrinol. 18 2740 2750 (2004)
PMID: 15308688 DOI: 10.1210/me.2004-0248

Abstact

IGFs are important mediators of growth. IGF binding proteins (IGFBPs) 1-6 regulate IGF actions and have IGF-independent actions. The C-terminal domains of IGFBPs contribute to high-affinity IGF binding and modulation of IGF actions and confer some IGF-independent properties, but understanding how they achieve this has been constrained by the lack of a three-dimensional structure. We therefore determined the solution structure of the C-domain of IGFBP-6 using nuclear magnetic resonance (NMR). The domain consists of a thyroglobulin type 1 fold comprising an alpha-helix followed by a loop, a three-stranded antiparallel beta-sheet incorporating a second loop, and finally a disulfide-bonded flexible third loop. The IGF-II binding site on the C-domain was identified by examining NMR spectral changes upon complex formation. It consists of a largely hydrophobic surface patch involving the alpha-helix, the first beta-strand, and the first and second loops. The site was confirmed by mutagenesis of several residues, which resulted in decreased IGF binding affinity. The IGF-II binding site lies adjacent to surfaces likely to be involved in glycosaminoglycan binding of IGFBPs, which might explain their decreased IGF affinity when bound to glycosaminoglycans, and nuclear localization. Our structure provides a framework for understanding the roles of IGFBP C-domains in modulating IGF actions and conferring IGF-independent actions, as well as ultimately for the development of therapeutic IGF inhibitors for diseases including cancer.

Legend

Protein

Chemical

Disease

Primary Citation of related structures